AU2017290143A1 - Depot formulations - Google Patents

Depot formulations Download PDF

Info

Publication number
AU2017290143A1
AU2017290143A1 AU2017290143A AU2017290143A AU2017290143A1 AU 2017290143 A1 AU2017290143 A1 AU 2017290143A1 AU 2017290143 A AU2017290143 A AU 2017290143A AU 2017290143 A AU2017290143 A AU 2017290143A AU 2017290143 A1 AU2017290143 A1 AU 2017290143A1
Authority
AU
Australia
Prior art keywords
composition
weight
amount ranging
saib
sirolimus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017290143A
Other languages
English (en)
Inventor
Weiqi Lin
Naoki Matsumoto
Sreenivasu Mudumba
Komei OKABE
Huey-Ching Lin Su
Wilma Tamraz
Kazuhito Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Durect Corp
Original Assignee
Santen Pharmaceutical Co Ltd
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd, Durect Corp filed Critical Santen Pharmaceutical Co Ltd
Publication of AU2017290143A1 publication Critical patent/AU2017290143A1/en
Priority to AU2023202823A priority Critical patent/AU2023202823A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C31/02—Monohydroxylic acyclic alcohols
    • C07C31/08—Ethanol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/26—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/12—Disaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
AU2017290143A 2016-06-30 2017-06-29 Depot formulations Abandoned AU2017290143A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023202823A AU2023202823A1 (en) 2016-06-30 2023-05-05 Depot formulations

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662356613P 2016-06-30 2016-06-30
US62/356,613 2016-06-30
US201662440658P 2016-12-30 2016-12-30
US62/440,658 2016-12-30
PCT/US2017/039968 WO2018005777A1 (en) 2016-06-30 2017-06-29 Depot formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023202823A Division AU2023202823A1 (en) 2016-06-30 2023-05-05 Depot formulations

Publications (1)

Publication Number Publication Date
AU2017290143A1 true AU2017290143A1 (en) 2019-02-21

Family

ID=60786467

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017290143A Abandoned AU2017290143A1 (en) 2016-06-30 2017-06-29 Depot formulations
AU2023202823A Abandoned AU2023202823A1 (en) 2016-06-30 2023-05-05 Depot formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023202823A Abandoned AU2023202823A1 (en) 2016-06-30 2023-05-05 Depot formulations

Country Status (16)

Country Link
US (2) US10668011B2 (https=)
EP (1) EP3478285A4 (https=)
JP (2) JP7051721B2 (https=)
KR (1) KR20190025635A (https=)
CN (2) CN115645399A (https=)
AU (2) AU2017290143A1 (https=)
BR (1) BR112018077259A2 (https=)
CA (1) CA2972296A1 (https=)
GE (1) GEP20207204B (https=)
IL (1) IL263714A (https=)
MX (1) MX387477B (https=)
PH (1) PH12018502615A1 (https=)
SG (1) SG11201810618QA (https=)
TW (1) TWI765898B (https=)
UA (1) UA124768C2 (https=)
WO (2) WO2018005777A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI731853B (zh) * 2015-03-18 2021-07-01 日商參天製藥股份有限公司 徐放性醫藥組成物及其安定化方法
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
KR20190025635A (ko) 2016-06-30 2019-03-11 듀렉트 코퍼레이션 데포 제형
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
CN112423740A (zh) * 2018-05-01 2021-02-26 奇比有限公司 用于将药物持续递送至视网膜的滴眼剂制剂和方法
AU2019263302C1 (en) 2018-05-01 2024-10-31 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye
WO2020242862A1 (en) * 2019-05-24 2020-12-03 Piedmont Animal Health Inc. Long-acting injectable formulations and use thereof
CN113117049A (zh) * 2019-12-31 2021-07-16 齐鲁制药有限公司 一种索玛鲁肽原位凝胶制剂及其制备方法

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443340A (en) 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
JPH04230389A (ja) 1990-07-16 1992-08-19 American Home Prod Corp ラパマイシン誘導体
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
ZA924953B (en) 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
KR970007322B1 (ko) 1991-12-19 1997-05-07 미쓰이도오아쓰 가가쿠 가부시키가이샤 폴리히드록시 카르복실산 및 그 제조방법
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5242910A (en) 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
US5536729A (en) 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5968542A (en) 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
US7833543B2 (en) * 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US5747058A (en) 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
PT1006935E (pt) * 1995-06-07 2005-06-30 Durect Corp Sistema de entrega controlada liquido de alta viscosidade
US5989591A (en) 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
DK1372729T3 (da) 2001-02-23 2009-06-22 Genentech Inc Nedbrydelige polymere til injektion
DE60325742D1 (de) 2002-07-31 2009-02-26 Alza Corp Injizierbare multimodale polymere depotzusammensetzungen und ihre verwendungen
US8163726B2 (en) 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
ATE418323T1 (de) 2002-11-06 2009-01-15 Alza Corp Depot-formulierungen mit verzögerter freisetzung
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
AU2004219595A1 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
CA2539324A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
SI2415484T1 (sl) 2004-09-17 2014-10-30 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
EP2452670A1 (en) 2004-10-01 2012-05-16 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8313763B2 (en) * 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
US8663639B2 (en) * 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR20070121754A (ko) * 2005-03-21 2007-12-27 마커사이트, 인코포레이티드 질환 또는 상태의 치료를 위한 약물 송달 시스템
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
CN1973822A (zh) 2006-12-20 2007-06-06 山东蓝金生物工程有限公司 一种含雷帕霉素的抗癌组合物
CA2671925A1 (en) 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
DK2167039T3 (en) 2007-05-18 2017-01-09 Durect Corp Improved depot formulations
WO2009023877A2 (en) 2007-08-16 2009-02-19 Macusight, Inc. Formulations for treatment of ocular diseases or conditions
JP2011506319A (ja) 2007-12-06 2011-03-03 デュレクト コーポレーション 疼痛、関節炎症状、または慢性疾患に伴う炎症の治療に有用な方法
WO2009100222A1 (en) 2008-02-08 2009-08-13 Qps Llc Non-polymeric compositions for controlled drug delivery
US20120114637A1 (en) 2009-05-04 2012-05-10 Santen Pharmaceutical Co., Ltd. Mtor pathway inhibitors for treating ocular disorders
JP2013543898A (ja) 2010-11-24 2013-12-09 デュレクト コーポレイション 生体分解性薬物送達組成物
US20140294977A1 (en) 2011-11-23 2014-10-02 Durect Corporation Radiation-Sterilized Biodegradable Drug Delivery Composition
RU2672596C2 (ru) 2012-01-23 2018-11-16 Аллерган, Инк. Биологически разлагаемые или биологически разрушаемые микросферы или микрочастицы длительного высвобождения, суспендированные в затвердевающем депообразующем инъекцируемом лекарственном составе
HK1220628A1 (zh) 2013-03-11 2017-05-12 Durect Corporation 包含高粘度液体载体的可注射控制释放组合物
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
JP2016514692A (ja) 2013-03-15 2016-05-23 デュレクト コーポレーション チキソトロピーならびに強化された溶解再現性及び安定性を有する組成物
ES2902951T3 (es) 2013-05-24 2022-03-30 Icon Bioscience Inc Uso de dexametasona de liberación sostenida en la inflamación después de cirugía de cataratas
EP3220887A1 (en) 2014-11-21 2017-09-27 Technical University of Denmark Gel formulations for local drug release
TWI731853B (zh) 2015-03-18 2021-07-01 日商參天製藥股份有限公司 徐放性醫藥組成物及其安定化方法
EP3318280A4 (en) 2015-07-01 2018-08-22 Santen Pharmaceutical Co., Ltd Depot preparation containing citric acid ester
KR20190025635A (ko) 2016-06-30 2019-03-11 듀렉트 코퍼레이션 데포 제형
EP3565553B1 (en) 2017-01-06 2023-04-26 Santen Pharmaceutical Co., Ltd. Intratumoral administration of sirolimus for treatment of prostate cancer

Also Published As

Publication number Publication date
US10668011B2 (en) 2020-06-02
WO2019133735A1 (en) 2019-07-04
US20200352852A1 (en) 2020-11-12
GEAP202014989A (en) 2020-07-27
CN115645399A (zh) 2023-01-31
IL263714A (en) 2019-01-31
EP3478285A4 (en) 2020-07-22
PH12018502615A1 (en) 2019-09-30
CN109310680B (zh) 2022-11-01
CA2972296A1 (en) 2017-12-30
GEP20207204B (en) 2020-12-25
SG11201810618QA (en) 2019-01-30
KR20190025635A (ko) 2019-03-11
JP2022088568A (ja) 2022-06-14
TWI765898B (zh) 2022-06-01
UA124768C2 (uk) 2021-11-17
TW201811374A (zh) 2018-04-01
JP7051721B2 (ja) 2022-04-11
WO2018005777A1 (en) 2018-01-04
BR112018077259A2 (pt) 2019-06-18
MX387477B (es) 2025-03-18
AU2023202823A1 (en) 2023-05-25
EP3478285A1 (en) 2019-05-08
US20180000729A1 (en) 2018-01-04
JP2019526532A (ja) 2019-09-19
MX2018016424A (es) 2019-08-12
CN109310680A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
US10668011B2 (en) Depot formulations
US20230146925A1 (en) Depot formulations
US20200383957A1 (en) Depot formulations
KR20080094814A (ko) 안정한 제제와 그 제조 및 사용 방법
KR20150041794A (ko) 오피오이드 제형
WO2018126049A1 (en) Depot formulations
US20220265830A1 (en) Long-acting formulations and vehicles
AU2013202476B2 (en) Improved depot formulations

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted